JP2013512268A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013512268A5 JP2013512268A5 JP2012541422A JP2012541422A JP2013512268A5 JP 2013512268 A5 JP2013512268 A5 JP 2013512268A5 JP 2012541422 A JP2012541422 A JP 2012541422A JP 2012541422 A JP2012541422 A JP 2012541422A JP 2013512268 A5 JP2013512268 A5 JP 2013512268A5
- Authority
- JP
- Japan
- Prior art keywords
- mitotic checkpoint
- compounds
- schmidt
- present
- inhibition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000017205 mitotic cell cycle checkpoint Effects 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 231100001075 aneuploidy Toxicity 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000009038 pharmacological inhibition Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 150000008523 triazolopyridines Chemical class 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09075534A EP2343295A1 (en) | 2009-11-30 | 2009-11-30 | Triazolopyridine derivates |
| EP09075534.9 | 2009-11-30 | ||
| PCT/EP2010/068298 WO2011064328A1 (en) | 2009-11-30 | 2010-11-26 | Triazolopyridine derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013512268A JP2013512268A (ja) | 2013-04-11 |
| JP2013512268A5 true JP2013512268A5 (OSRAM) | 2014-01-09 |
| JP5805654B2 JP5805654B2 (ja) | 2015-11-04 |
Family
ID=42027882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012541422A Expired - Fee Related JP5805654B2 (ja) | 2009-11-30 | 2010-11-26 | トリアゾロピリジン誘導体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20130121994A1 (OSRAM) |
| EP (2) | EP2343295A1 (OSRAM) |
| JP (1) | JP5805654B2 (OSRAM) |
| CN (1) | CN102753547B (OSRAM) |
| CA (1) | CA2782012A1 (OSRAM) |
| ES (1) | ES2532655T3 (OSRAM) |
| WO (1) | WO2011064328A1 (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2343297A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridines |
| UY33452A (es) | 2010-06-16 | 2012-01-31 | Bayer Schering Pharma Ag | Triazolopiridinas sustituidas |
| TWI541243B (zh) | 2010-09-10 | 2016-07-11 | 拜耳知識產權公司 | 經取代咪唑并嗒 |
| WO2012080229A1 (en) | 2010-12-17 | 2012-06-21 | Bayer Pharma Aktiengesellschaft | Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders |
| CA2821837A1 (en) | 2010-12-17 | 2012-06-21 | Bayer Intellectual Property Gmbh | 2-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| WO2012080234A1 (en) | 2010-12-17 | 2012-06-21 | Bayer Pharma Aktiengesellschaft | Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| US20140135319A1 (en) | 2010-12-17 | 2014-05-15 | Bayer Intellectual Property Gmbh | 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| US20140187548A1 (en) | 2010-12-17 | 2014-07-03 | Bayer Intellectual Property Gmbh | 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| CA2821827A1 (en) | 2010-12-17 | 2012-06-21 | Bayer Intellectual Property Gmbh | 6-thio-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| ES2571741T3 (es) | 2011-03-31 | 2016-05-26 | Bayer Ip Gmbh | Bencimidazoles sustituidos como inhibidores de Mps-1 quinasa |
| JP5951750B2 (ja) | 2011-04-06 | 2016-07-13 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 置換イミダゾピリジン類およびその中間体 |
| WO2012160029A1 (en) | 2011-05-23 | 2012-11-29 | Bayer Intellectual Property Gmbh | Substituted triazolopyridines |
| UA112096C2 (uk) * | 2011-12-12 | 2016-07-25 | Байєр Інтеллектуал Проперті Гмбх | Заміщені триазолопіридини та їх застосування як інгібіторів ttk |
| US9512126B2 (en) | 2012-03-14 | 2016-12-06 | Bayer Intellectual Property Gmbh | Substituted imidazopyridazines |
| EP2872506A1 (en) * | 2012-07-10 | 2015-05-20 | Bayer Pharma Aktiengesellschaft | Method for preparing substituted triazolopyridines |
| WO2014020043A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| WO2014020041A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| CN103965199B (zh) * | 2013-02-02 | 2017-07-07 | 广东东阳光药业有限公司 | 一种芳杂环化合物、包含它的药物组合物及其用途 |
| AR096469A1 (es) * | 2013-06-06 | 2015-12-30 | Bayer Pharma AG | Composiciones farmacéuticas que comprenden compuestos del tipo triazolpiridinas |
| AP2015008898A0 (en) | 2013-06-11 | 2015-12-31 | Bayer Pharma AG | Prodrug derivatives of substituted triazolopyridines |
| US20160128988A1 (en) | 2013-06-11 | 2016-05-12 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor |
| EP2860177A3 (en) | 2013-09-20 | 2015-06-10 | Bayer Intellectual Property GmbH | Synthesis of functionalized arenes |
| JP6993233B2 (ja) | 2015-04-17 | 2022-01-13 | ネザーランズ トランスレーショナル リサーチ センター ビー．ブイ． | Ｔｔｋ阻害剤化学療法の為の予後バイオマーカー |
| GB201522532D0 (en) * | 2015-12-21 | 2016-02-03 | Cancer Rec Tech Ltd | Novel pyrrolo[3,2-c]pyridine-6-amino derivatives |
| CN107641118B (zh) * | 2016-07-22 | 2020-11-06 | 爱科诺生物医药股份有限公司 | 具有细胞坏死抑制活性的化合物及其组合物和应用 |
| AU2020257301B2 (en) | 2019-04-18 | 2025-10-23 | The Johns Hopkins University | Substituted 2-amino-pyrazolyl-(1,2,4)triazolo(1,5a) pyridine derivatives and use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| WO2006018325A1 (en) | 2004-08-17 | 2006-02-23 | Galderma Research & Development, S.N.C. | Novel biaromatic compounds which activate receptors of ppar type and their use in cosmetic or pharmaceutical compositions |
| BRPI0716239A2 (pt) * | 2006-08-30 | 2013-08-13 | Cellzome Ltd | derivados de triazol como inibidores de cinase |
| MX2010000716A (es) * | 2007-07-18 | 2010-03-26 | Novartis Ag | Compuestos de heteroarilo biciclicos y su uso como inhibidores de cinasa. |
| BRPI0815709A2 (pt) * | 2007-08-23 | 2017-06-13 | Astrazeneca Ab | composro, composição farmacêutica, e, uso de um composto. |
| GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| CA2706578A1 (en) * | 2007-11-27 | 2009-06-04 | Cellzome Limited | Amino triazoles as pi3k inhibitors |
| WO2010092015A1 (en) * | 2009-02-10 | 2010-08-19 | Cellzome Limited | Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors |
| US20120041195A1 (en) * | 2009-02-13 | 2012-02-16 | Fovea Pharmaceuticals | Heterocyclic compounds |
-
2009
- 2009-11-30 EP EP09075534A patent/EP2343295A1/en not_active Withdrawn
-
2010
- 2010-11-26 ES ES10787724.3T patent/ES2532655T3/es active Active
- 2010-11-26 WO PCT/EP2010/068298 patent/WO2011064328A1/en not_active Ceased
- 2010-11-26 CA CA2782012A patent/CA2782012A1/en not_active Abandoned
- 2010-11-26 US US13/512,721 patent/US20130121994A1/en not_active Abandoned
- 2010-11-26 CN CN201080061523.7A patent/CN102753547B/zh not_active Expired - Fee Related
- 2010-11-26 JP JP2012541422A patent/JP5805654B2/ja not_active Expired - Fee Related
- 2010-11-26 EP EP10787724.3A patent/EP2507236B1/en not_active Not-in-force
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013512268A5 (OSRAM) | ||
| JP2013512263A5 (OSRAM) | ||
| JP2013503824A5 (OSRAM) | ||
| JP2013512264A5 (OSRAM) | ||
| Duan et al. | EZH2: a novel target for cancer treatment | |
| Liu et al. | Targeting CDK12 for cancer therapy: function, mechanism, and drug discovery | |
| Do et al. | Wee1 kinase as a target for cancer therapy | |
| ES2648876T3 (es) | Dihidropirido[3,4-b]pirazinonas sustituidas como inhibidores duales de proteínas BET y quinasas tipo polo | |
| Jhaveri et al. | HSP90 inhibitors for cancer therapy and overcoming drug resistance | |
| JP2022050493A (ja) | 癌を治療する方法における使用のための毛細血管拡張性運動失調症の変異したＲａｄ３関連タンパク質キナーゼ（ＡＴＲ）の阻害剤 | |
| TW202045181A (zh) | 細胞週期蛋白依賴性激酶2生物標記物及其用途 | |
| EP4335511A3 (en) | Small molecule trail gene induction by normal and tumor cells as an anticancer therapy | |
| JP2016501221A5 (OSRAM) | ||
| JP2021502388A (ja) | Ａｓｈ１ｌ阻害剤及びそれを用いた治療方法 | |
| JP2018510193A (ja) | Ｌｓｄ１阻害剤としてのヘテロ環式化合物 | |
| NZ628407A (en) | Treatment of cancer with tor kinase inhibitors | |
| AU2018212647A1 (en) | Combination therapy involving diaryl macrocyclic compounds | |
| JP2015512943A5 (OSRAM) | ||
| JP2009507918A5 (OSRAM) | ||
| JP2015508103A5 (OSRAM) | ||
| PH12014500103A1 (en) | Pyridin-2(1h)-one derivatives as jak inhibitors | |
| BR112014027337A2 (pt) | composições orgânicas para tratar doenças relacionadas com kras | |
| WO2019015561A1 (en) | TREATMENT OF CANCERS USING A COMBINATION COMPRISING INHIBITORS OF PARP, TEMOZOLOMIDE AND / OR RADIOTHERAPY | |
| JP2013521314A5 (OSRAM) | ||
| PH12014501832A1 (en) | Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme |